Methods
Published on 21 Dec 2023
The microRNA target site profile is a novel biomarker in the immunotherapy response
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1225221
- 1,712 views
Type at least 3 characters
1,765 articles
Articles
Original Research
Published on 21 Dec 2023
A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1286754
- 2,711 views
- 3 citations
Review
Published on 15 Dec 2023
Autophagy-mediated nanomaterials for tumor therapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1194524
- 2,147 views
- 2 citations
Original Research
Published on 13 Dec 2023
Unraveling the safety of adjuvant radiotherapy in prostate cancer: impact of older age and hypofractionated regimens on acute and late toxicity - a multicenter comprehensive analysis
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1281432
- 1,038 views
Review
Published on 13 Dec 2023
Lipid kinases PIP5Ks and PIP4Ks: potential drug targets for breast cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1323897
- 1,961 views
- 1 citation
Case Report
Published on 07 Dec 2023
Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1283932
- 1,105 views
- 2 citations
Original Research
Published on 07 Dec 2023
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1184900
- 2,578 views
- 1 citation
Correction
Published on 07 Dec 2023
Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1334938
- 1,742 views
Original Research
Published on 06 Dec 2023
A tumor cell specific Zona Pellucida glycoprotein 3 RNA transcript encodes an intracellular cancer antigen
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1233039
- 1,401 views
Case Report
Published on 01 Dec 2023
Ribociclib-induced liver injury: a case report
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1256783
- 4,582 views
- 4 citations
Systematic Review
Published on 24 Nov 2023
Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1251895
- 4,102 views
- 1 citation
Mini Review
Published on 23 Nov 2023
Repurposing phenothiazines for cancer therapy: compromising membrane integrity in cancer cells
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1320621
- 2,710 views
- 5 citations
Original Research
Published on 20 Nov 2023
A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1049147
- 3,716 views
- 1 citation
Correction
Published on 20 Nov 2023
Corrigendum: Epigenetic-mediated downregulation of zinc finger protein 671 (ZNF671) predicts poor prognosis in multiple solid tumors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1334056
- 704 views
Review
Published on 16 Nov 2023
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1239118
- 3,243 views
- 2 citations
Original Research
Published on 14 Nov 2023
The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2023.1235158
- 1,168 views
- 1 citation